EUVIMEDEUVIMED entdecken
Crossref

Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real‐world study in China

Xiaoling Cheng iD, Zhifa Wang iD, Shuyue Dong, Jingyao Ma, Jinxi Meng, Xiaoling Wang, Runhui Wu iD

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Xiaoling Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by isolated thrombocytopenia and a haemorrhagic risk. Thrombopoietin receptor agonists (TPO‐RAs) are highly effective for ITP and are widely used to treat patients with steroid treatment failure or dependency. However, although treatment response to TPO‐RAs may differ according to the type, the potential impact of switching from eltrombopag (ELT) to avatrombopag (AVA) with respect to efficacy or tolerance in children remains unknown. This study aimed to evaluate the outcomes of switching from ELT to AVA in paediatric patients with ITP. We retrospectively evaluated children with chronic immune thrombocytopenia (cITP) switched from ELT to AVA owing to treatment failure at the Hematology‐Oncology Center of Beijing Children's Hospital between July 2021 and May 2022. Overall, 11 children (seven and four boys and girls respectively) with a median age of 8.3 (range: 3.8–15.3) years were included. The overall response and complete response (platelet [PLT] count ≥100 × 10 9 /L) rates during AVA treatment were 81.8% (9/11) and 54.6% (6/11) respectively. The median PLT count was significantly increased from ELT to AVA (7 [range: 2–33] × 10 9 /L vs. 74 [15–387] × 10 9 /L; p = 0.007). The median time to PLT count ≥30 × 10 9 /L was 18 (range: 3–120) days. Overall, 7/11 patients (63.6%) used concomitant medications, and concomitant medication use was gradually discontinued within 3–6 months after AVA initiation. In conclusion, AVA after ELT is effective in the heavily pretreated paediatric cITP population, with high response rates even in those with an inadequate response to a prior TPO‐RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicThrombocytopeniaMaleFemaleHumansChildChild, PreschoolAdolescentRetrospective StudiesBenzoatesHydrazinesTreatment FailureThrombopoietinRecombinant Fusion ProteinsPyrazolesThiazolesThiophenes

Stichwörter der Autor:innen

avatrombopagchildreneltrombopagimmune thrombocytopeniaswitch

Substanzen

BenzoatesHydrazinesThrombopoietinRecombinant Fusion ProteinseltrombopagPyrazolesavatrombopagThiazolesThiophenes

Autor:innen und Institutionen

  • Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, Beijing, China.
  • Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Xiaoling Cheng, Zhifa Wang, Runhui Wu

Zitieren

APA

Cheng, X., Wang, Z., Dong, S., Ma, J., Meng, J., Wang, X., & Wu, R. (2023). Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real‐world study in China. British Journal of Haematology. https://doi.org/10.1111/bjh.18864

Vancouver

Cheng X, Wang Z, Dong S, Ma J, Meng J, Wang X, et al. Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real‐world study in China. British Journal of Haematology. 2023. doi:10.1111/bjh.18864

BibTeX
@article{Cheng2023,
  author = {Cheng, Xiaoling and Wang, Zhifa and Dong, Shuyue and Ma, Jingyao and Meng, Jinxi and Wang, Xiaoling and Wu, Runhui},
  title = {Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real‐world study in China},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18864}
}
Kostenlos starten →